26 reports

  • GLOBAL ANTIVIRAL DRUGS MARKET SEGMENTATION BY THERAPIES
  • VIRAL DISEASE
  • Influenza
  • World
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc

PRIOR TO JOINING GLOBALDATA, NATASHA WORKED AS AN EPIDEMIOLOGIST FOR THREE YEARS IN THE HIV/ AIDS SURVEILLANCE PROGRAM AT THE MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH (MDPH).

  • Influenza
  • Europe
  • CSL Limited
  • Daiichi Sankyo Company
  • Mitsubishi Corporation
  • 22.1 MALTA SEASONAL INFLUENZA VACCINATED TOTAL POPULATION

In Malta, seasonal influenza vaccination is recommended for all aged ## years and over, children between ## months and ## months old, and persons of any age suffering from chronic diseases of the lungs, heart, liver, kidney, diabetes, and any immunodeficiency conditions, including HIV and

  • Influenza
  • Vaccine
  • Europe
  • Forecast
  • Market Size
  • 6.1 Malta Seasonal Influenza Vaccinated Total Population

In Malta, seasonal influenza vaccination is recommended for all aged ## years and over, children between ## months and ## months old, and persons of any age suffering from chronic diseases of the lungs, heart, liver, kidney, diabetes, and any immunodeficiency conditions, including HIV and

  • Influenza
  • Vaccine
  • Europe
  • Forecast
  • Market Size
  • Which factors contribute to the severity of seasonal influenza?

Young children and the elderly are the most at risk of severe and/ or fatal influenza, as well as consumers with underlying health conditions, such as heart disease or HIV/ AIDS.

  • Cough Cold
  • Influenza
  • United States
  • Demand
  • Mondelez International, Inc.
  • 21.1 MALTA SEASONAL INFLUENZA VACCINATED TOTAL POPULATION

In Malta, seasonal influenza vaccination is recommended for all aged ## years and over, children between ## months and ## months old, and persons of any age suffering from chronic diseases of the lungs, heart, liver, kidney, diabetes, and any immunodeficiency conditions, including HIV and

  • Influenza
  • Vaccine
  • Europe
  • Forecast
  • Market Size

Prior to joining GlobalData, Natasha worked as an epidemiologist for three years in the HIV/ AIDS Surveillance Program at the Massachusetts Department of Public Health (MDPH).

  • Influenza
  • Vaccine
  • Germany
  • Japan
  • Forecast
  • EPIVAX, INC. - RESEARCH AND DEVELOPMENT OVERVIEW
  • Infectious Disease
  • Influenza
  • Vaccine
  • United States
  • EpiVax, Inc.
  • NVINF-2 - DRUG PROFILE

It offers pipeline product portfolio such as drugs for various indications such as HIV, influenza, flaviviruses including dengue and eye drops, among others.

  • Influenza
  • Vaccine
  • United States
  • Product Initiative
  • NanoViricides, Inc.
  • NVINF-2 - DRUG PROFILE

Its pipeline product portfolio includes drugs for various indications such as HIV, influenza, flaviviruses including dengue and eye drops, among others.

  • Influenza
  • Pharmaceutical
  • Vaccine
  • United States
  • Product Initiative
  • NVINF-2 - DRUG PROFILE

PaxVax also develops anthrax vaccine, Cholera Vaccine, HIV vaccine, dengue vaccine candidates.

  • Influenza
  • Pharmaceutical
  • Vaccine
  • United States
  • Product Initiative
  • Clinical Trial Profile Snapshots

HIV Trials ## Jan 2015 ## Oct 2017 Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) # of Subjects Planned # of Location(s) # of Investigator(s) A Double-Blind, Randomized, Controlled Trial to Evaluate the Saf

  • Infectious Disease
  • Influenza
  • Pathology
  • World
  • Product Initiative
  • NVINF-2 - DRUG PROFILE

THE DRUG CANDIDATE IS DEVELOPED BASED ON VIRUS ANALYSIS TECHNOLOGY PLATFORM AND A CHEMICAL SYNTHETIC METHOD CALLED THIONATION WHICH AIDS IN MODIFYING NUCLEOZIN AND ITS DERIVATIVES.

  • Influenza
  • Pharmaceutical
  • Vaccine
  • United States
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

HIV- INFECTED ADULTS SAFETY OF AND IMMUNOGENICITY TO AN H##N## INFLUENZA VACCINE IN HIV-INFECTED ADULTS (VIP-H##N##) GDCT## NCT##, INFECTIOUS DISEASE HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTIONS (AIDS), INFLUENZA A VIRUS, H##N## SUBTYPE INFECTIONS, UNSPECIFI

  • Drug Discovery And Development
  • Influenza
  • World
  • Product Initiative
  • GlaxoSmithKline plc
  • CLINICAL TRIAL PROFILE SNAPSHOTS

HIV Trials ## Jan 2015 ## Oct 2017 ## ## ## Clinical Trial profile. ## Trial Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Estimated Start Date Estimated Completion Date # of Subjects Planned # of L

  • Clinical Trial
  • Influenza
  • Pharmaceutical
  • World
  • Product Initiative
  • RINTATOLIMOD - DRUG PROFILE

PaxVax also develops anthrax vaccine, Cholera Vaccine, HIV vaccine, dengue vaccine candidates.

  • Influenza
  • United States
  • World
  • Product Initiative
  • Hemispherx Biopharma, Inc.
  • Clinical Trial Profile Snapshots

HIV-Infected Compared to HIV-Uninfected Persons Immunogenicity of Novel H##N## Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons GDCT## NCT##, IDCRP-## Infectious Disease Influenza A Virus, H##N## Subtype Infections, Unspecified Influenza V

  • Clinical Trial
  • Influenza
  • World
  • Product Initiative
  • GlaxoSmithKline plc

HIV Infection Prevention of Pneumonia in Children (Age: ## to ## years) with HIV Infection GDCT## CTRI/ 2013/ ##/ ##, PPH##; X##/ ##/ ##-BD Infectious Disease Haemophilus influenzae Type B Infections, Human Immunodeficiency Virus (HIV) Infecti

  • Infectious Disease
  • Influenza
  • World
  • Product Initiative
  • GlaxoSmithKline plc
  • Daiichi Sankyo Company, Limited - Dormant Developmental Projects,2016

THE DRUG CANDIDATE BY INHIBITING THE DR## ACTIVITY AIDS IN THE TREATMENT OF UNDERLYING CAUSE.

  • Cancer
  • Influenza
  • Monoclonal Antibody
  • Therapy
  • Daiichi Sankyo Company

It was also under development for the treatment of melanoma, renal cell carcinoma and HIV / AIDS.

  • Influenza
  • United States
  • Company
  • Product Initiative
  • Hemispherx Biopharma, Inc.
  • Clinical Trial Profile Snapshots

HIV Trials ## Jan 2015 ## Oct 2017 Clinical Trial profile. ## Trial Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Estimated Start Date # of Subjects Planned # of Location(s) # of Investigator(s) Clin

  • Influenza
  • Pathology
  • World
  • Product Initiative
  • GlaxoSmithKline plc
  • Clinical Trial Profile Snapshots

HIV-Infected Compared to HIV-Uninfected Persons Immunogenicity of Novel H##N## Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons GDCT## NCT##, IDCRP-## Infectious Disease H##N## Infection, Influenza Completed Phase IV Observational inactiva

  • Clinical Trial
  • Influenza
  • World
  • Product Initiative
  • GlaxoSmithKline plc
  • Clinical Trial profile. 215 Trial Title
  • Clinical Trial Profile Snapshots
  • Clinical Trial
  • Influenza
  • Pharmaceutical
  • World
  • GlaxoSmithKline plc
  • Clinical Trial profile. 197 Trial Title
  • Clinical Trial Profile Snapshots

HIV-Infected Adults Safety of and Immunogenicity to an H##N## Influenza Vaccine in HIV-infected Adults (VIP-H##N##) GDCT## NCT##, Infectious Disease H##N## Infection, HIV / AIDS, HIV-## Infection, Influenza (T-Cell Surface Glycoprotein CD## (T-Cel

  • Clinical Trial
  • Influenza
  • Pharmaceutical
  • World
  • GlaxoSmithKline plc

It was also under development for the treatment of melanoma, renal cell carcinoma and HIV / AIDS.

  • Influenza
  • United States
  • Company
  • Product Initiative
  • Hemispherx Biopharma, Inc.

HIV) Infected Infants, HIV Exposed Uninfected Infants and Unexposed Uninfected Infants Receiving the Pneumococcal Vaccine GSK ##A Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfe

  • Infectious Disease
  • Influenza
  • World
  • Product Initiative
  • GlaxoSmithKline plc